View Older Stories View More Recent Stories
-
Adlai Nortye clears regulatory hurdle for AN4035 cancer drug trial
-
Smartkem to acquire Ferrox Critical Minerals in $125M all-stock deal
-
CMS grants Ceribell up to $2,171 per-case payment for delirium monitor
-
VisionWave files international trademark for its StratumAI platform
-
Douglas Dynamics (PLOW) Tops Q2 EPS by 4c ; Offers Guidance
-
BCB Bancorp posts $14.8M Q2 loss on loan provisions, goodwill charge
-
D-Wave and Nasdaq Verafin to explore quantum computing for fraud
-
Chevron expands base oils distribution with two North American partners
-
FDA grants orphan drug status to Zai Lab's zoci for neuroendocrine carcinomas
-
Wayfair plans Pittsburgh store set to open in 2027
-
Aurora Mobile's GPTBots.ai releases LoopAgent for enterprise AI tasks
-
Genprex partners with Roche Diagnostics on NSCLC biomarker studies
-
KKR closes $19.2 billion infrastructure fund, its largest to date
-
CNH Global N.V. (CNH) Tops Q2 EPS by 3c, Offers Guidance
-
Westwater Resources (WWR) PT Lowered to $1.50 at H.C. Wainwright
-
Netsertive Announces the Latest AI-Native Version of MLX, Introduces Version 3.0 of its Multi-Location Experience Platform
-
Enlivex Therapeutics (ENLV) PT Raised to $80 at H.C. Wainwright
-
Balchem (BCPC) PT Raised to $215 at H.C. Wainwright
-
Bausch & Lomb Corp. (BLCO) PT Raised to $21 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
H.C. Wainwright Reiterates Buy Rating on Sophia Genetics SA (SOPH)
-
H.C. Wainwright Reiterates Neutral Rating on Evommune Inc (EVMN)
-
H.C. Wainwright Reiterates Buy Rating on Precision BioSciences Inc. (DTIL)
-
H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)
-
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
-
Northland Upgrades inTEST Corp. (INTT) to Outperform
-
H.C. Wainwright Reiterates Buy Rating on Strategy (MSTR)
-
Roblox Corp. (RBLX) PT Lowered to $46 at Wells Fargo
-
Berenberg Upgrades Mersen SA (MRN:FP) to Buy
-
Newell Brands Inc (NWL) PT Raised to $11 at Canaccord
-
Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord
-
Merit Medical Systems, Inc. (MMSI) PT Raised to $94 at Canaccord
-
DexCom (DXCM) PT Raised to $90 at Canaccord
-
Goldman Sachs warns on Fed communication strategy risks
-
Abbvie (ABBV) PT Raised to $290 at Canaccord
-
Santa Rally window opens in 3 months: small-caps and tech lead the way
-
Echo Global Logistics (ECHO) Tops Q2 EPS by 2433c
-
Tesla's Spain sales drop 81% in July to 131 vehicles
-
Easterly Government Properties (DEA) Tops Q2 EPS by 1c ; Offers EPS Guidance Range
-
Jaunt Air Mobility picks Calogy Solutions for VTOL drone battery system
-
Supernus and Indivior agree to all-stock merger of equals
-
Parsons wins design role in $227M South Carolina interchange project
-
American Bitcoin Corp. (ABTC) reported Q2 Revenue
-
AZZ Inc. names Rhonda Davenport as chief human resources officer
-
Loews Corp. (L) Reports Q2 EPS of $2.16
-
Raymond James Reiterates Underperform Rating on Aon Corp (AON)
-
Bernstein raises server shipment forecast as AI infrastructure spending grows
-
Bernstein SocGen Group Downgrades Wingstop (WING) to Market Perform
-
Rockwell Automation positioned for Q2 strength on US factory demand
-
Fed's Williams says rate hikes possible if inflation persists
